This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Mosaicism, 45,X/other cell line(s) with abnormal sex chromosome — Turner syndrome variant섞임증, 이상 성염색체를 가진 45,X/기타 세포열

Contents and key information
ItemDetails
A. Classification codesICD-10: Q96.4 | Special Copayment Reduction: V021 | Re-certification cycle: 5 years
B. SynonymsNone
C. Adult onsetFirst presentation in adulthood possible — variant forms involving abnormal sex chromosomes such as isochromosomes or deletions have diverse phenotypes and are sometimes first diagnosed in adulthood during infertility evaluation.
1. HistoryTurner variant mosaics described in the 1960s → isochromosome X and deletion forms identified in the 1970s–80s → detailed classification established after the introduction of molecular cytogenetics.
2. CausesCoexistence of an abnormal sex chromosome generated during mitosis (isochromosome, deletion, ring chromosome, etc.) and a 45,X cell line. The originating mutation arises sporadically during early development.
3. GeneticsDiverse, including 45,X/46,X,i(Xq), 45,X/46,X,del(X) and 45,X/46,X,r(X). i(Xq) is Xp deletion + Xq duplication. Severe intellectual disability in the ring X chromosome form when XIST is absent.
4. EpidemiologyTurner variants (Q96.2–Q96.4) are about 20–30% of all Turner syndrome. Of these, the frequency of the abnormal sex chromosome mosaic form (Q96.4) is about 5–15%.
5. PathophysiologyPhenotype is determined by the gene content deleted, which varies with the structure of the abnormal sex chromosome. i(Xq) emphasizes Xp haploinsufficiency; in r(X), phenotypic severity differs according to XIST expression.
6. SymptomsShort stature, ovarian failure, Turner physical features. The i(Xq) form has a phenotype close to the classic form. In the r(X) form, intellectual disability and autism spectrum when XIST is absent.
7. SignsCardiovascular malformations, renal abnormalities, autoimmune thyroiditis. Increased risk of autoimmune disease in the i(Xq) form. Neurodevelopmental abnormalities with r(X) + absent XIST.
8. ScreeningPrenatal cfDNA (limited detection of abnormal sex chromosomes). Karyotype analysis for growth delay, developmental delay or delayed puberty in childhood. POI evaluation in adults.
9. DiagnosisKaryotype analysis + FISH + array CGH/SNP. XIST FISH essential in the r(X) form. FISH with Xp/Xq probes used to confirm the i(Xq) form.
10. TreatmentGrowth hormone, estrogen replacement. Additional neurodevelopmental support in the r(X) + absent XIST form. Cardiovascular, thyroid and bone density management.
11. PrognosisPrognosis varies by type of abnormal sex chromosome. The i(Xq) form is at the level of the classic form. The r(X) + absent XIST form has a poor prognosis due to neurodevelopmental disorders. Attention to cardiovascular risk is common to all.
12. PreventionGenetic counseling, invasive prenatal diagnosis (amniocentesis/CVS + FISH + array). Multidisciplinary follow-up to prevent complications. Establishment of an educational support plan.
13. References10 references (PMID / DOI)

1. History

The history of Turner syndrome variants begins in the 1960s, when the development of cytogenetic techniques led to the discovery that various sex chromosome abnormalities other than the simple 45,X karyotype are associated with the Turner phenotype. In the early 1960s, isochromosome X (i(Xq) — composed of two long arms of X) was found in patients with Turner syndrome, first drawing attention to the importance of genes on the short arm, Xp.

In the 1970s–1980s, various structural X chromosome abnormalities were described, including deletion of the long arm of X [del(Xq)], deletion of the short arm of X [del(Xp)] and ring X chromosome [r(X)]. In particular, reports that some patients with a mosaic form carrying a ring X chromosome (45,X/46,X,r(X)) had severe intellectual disability drew attention to clinical features different from the established perception of Turner syndrome. Then, in the 1990s, the presence or absence of the XIST (X-inactive specific transcript) gene was identified as the key factor determining the phenotypic severity of the ring X chromosome form.

With advances in molecular cytogenetics (FISH, array CGH, SNP arrays), the correlation between the gene content of each variant and phenotype began to be analyzed precisely. Since the 2000s, large cohort studies have confirmed that the isochromosome X form increases the risk of autoimmune diseases (diabetes, thyroiditis, inflammatory bowel disease) in women with Turner syndrome. Q96.4 is the ICD-10 code that classifies together all such variant mosaics in which a cell line containing a structurally abnormal sex chromosome coexists with a 45,X cell line.

Research is now moving toward precisely characterizing the gene content of the abnormal sex chromosome in each patient for use in phenotype prediction and personalized treatment. Particularly in complex mosaic forms that include r(X) or a small supernumerary marker chromosome (sSMC), genetic analysis combining multiple techniques has become essential.

2. Causes

The Q96.4 mosaic form arises from a combination of two mechanisms at the zygote or early embryonic stage. First, a 45,X cell line is formed by chromosomal nondisjunction or anaphase lag during mitosis; second, in an independent or sequential process, a structural rearrangement of the X chromosome occurs, forming a cell line containing an abnormal sex chromosome.

Isochromosome Xq [i(Xq)] is a structure in which the short arm of the X chromosome (Xp) is lost and the long arm (Xq) is duplicated, formed by abnormal division (centromeric misdivision) after X chromosome replication. Deletion of the short arm of X [del(Xp)] or of the long arm [del(Xq)] arises from unbalanced chromosomal rearrangement during mitosis or meiosis, respectively. A ring X chromosome [r(X)] is a structure in which both telomeres are deleted and the two ends are joined; it has high mitotic instability and the number of copies per cell tends to vary.

The reason these structural abnormalities coexist with a 45,X cell line is interpreted as follows: structurally unstable abnormal chromosomes are lost in some daughter cells during mitotic cell division, generating 45,X cells. The ring X chromosome form has a particularly strong tendency to do this. The originating mutation arises sporadically, and in most cases the parental germ cell karyotypes are normal. The recurrence risk is very low.

In variants that include a small marker chromosome (sSMC), it is important to determine whether the sSMC originates from the X chromosome or an autosome, and when an X-derived sSMC contains Y chromosome-specific sequences (SRY, TSPY), the risk of gonadoblastoma increases.

3. Genetics

The main karyotype variants under Q96.4 are classified as follows.

Molecular genetically, i(Xq) is confirmed by FISH showing loss of the Xp signal and a disomic Xq signal, and for r(X), inactivation status is determined by XIST FISH or methylation analysis. Array CGH/SNP arrays are essential for precise analysis of the gene content of each cell line.

4. General epidemiology

Turner syndrome variants (Q96.2–Q96.4, structural abnormalities and mosaic forms) account for about 20–30% of all Turner syndrome. Of these, Q96.4 (mosaic forms including an abnormal sex chromosome) is estimated at about 5–15%, and the exact frequency depends on the sensitivity of the diagnostic techniques applied.

The 45,X/46,X,i(Xq) mosaic form is one of the most common variants, at about 5–10% of all Turner syndrome. The 45,X/46,X,r(X) mosaic form is estimated at about 3–5% of all Turner syndrome; within it, the XIST-absent form is relatively rare but of very great clinical importance. Deletion forms and variants including an sSMC each have frequencies of less than a few percent.

As for racial and sex-specific variation, as with Turner syndrome overall it occurs only in girls, although some Y-containing sSMC forms may show a phenotypic male or ambiguous external genitalia. Age at diagnosis varies by variant: the r(X) + absent XIST form is often referred for developmental delay from early after birth, and the i(Xq) form commonly first presents with growth delay in childhood or delayed puberty.

In Korea, it is registered under rare disease Special Copayment Reduction V021 (Q96 group); there are no separate statistics by variant, and it is included in the statistics for Turner syndrome overall. As prenatal diagnosis increases, demand for genetic counseling on various abnormal sex chromosome variants is increasing.

5. Pathophysiology

The pathophysiology of Q96.4 is distinguished from the simple mosaic form (Q96.3) in that it is determined by the composition of genes lost or overexpressed according to the structure of the abnormal sex chromosome.

In the i(Xq) form, all genes of the short arm of X (Xp) are lost and the long arm of X (Xq) is overexpressed as isodisomy. SHOX gene deletion causes marked short stature, and deletion of Xp genes such as PAX6 causes ophthalmologic abnormalities in some. On the other hand, overexpression of Xq genes is known to be associated with an increased risk of autoimmune diseases (diabetes, autoimmune thyroiditis, inflammatory bowel disease, rheumatic diseases).

In the r(X) form, whether the XIST gene is included is key. XIST is located at Xq13.2 and produces a noncoding RNA that induces X chromosome inactivation (lyonization). If the r(X) contains XIST, it is normally inactivated, and the condition manifests at about the level of a Turner phenotype without abnormal gene expression. However, an r(X) that does not contain XIST is not inactivated, resulting in a state of gene excess (functional disomy or tetrasomy) in which both copies of several genes on the r(X) are expressed. This causes gene dosage imbalance during development, leading to severe intellectual disability, growth impairment, multiple congenital anomalies and autism spectrum disorder.

In the del(Xp) form, depending on the extent of the deletion, SHOX haploinsufficiency (short stature) is the main problem, and with more extensive Xp deletions, abnormalities of central nervous system development (NLGN4X, etc.) also occur. In the del(Xq) form, deletion of ovarian function-related genes in the Xq13–Xq26 region (excluding FMR1) is the main mechanism of premature ovarian insufficiency.

6. Symptoms

The clinical symptoms of Q96.4 vary with the type of abnormal sex chromosome. Short stature and hypogonadism, the main symptoms of Turner syndrome, appear in common, but each variant has additional specific symptoms.

45,X/46,X,i(Xq) mosaic form

The phenotype is close to classic Turner syndrome, with severe short stature and common ovarian failure. Physical features such as webbed neck and shield chest are relatively marked. Autoimmune thyroiditis occurs at a higher frequency (30–50%) than in other Turner variants. The risk of autoimmune diseases such as diabetes, inflammatory bowel disease (Crohn disease, ulcerative colitis) and rheumatoid arthritis is also increased. Cognitive function is generally normal.

45,X/46,X,r(X) XIST-containing form

Shows a relatively mild Turner phenotype, with short stature and hypogonadism as the main problems. Cognitive function is in the normal range.

45,X/46,X,r(X) XIST-absent form

Accompanied by severe intellectual disability (IQ <70), developmental delay, autism spectrum disorder, severe growth impairment and multiple congenital anomalies (heart, face). In addition to the Turner phenotype, distinct neurodevelopmental disorder symptoms come to the fore. Behavioral problems (aggression, stereotyped behavior, etc.) may be severe.

Deletion forms

Xp deletions mainly feature short stature and Turner physical features, whereas Xq deletions mainly present with premature ovarian insufficiency and mild physical features. They are often first discovered during infertility evaluation.

7. Signs

The main objective signs of Q96.4 are described by variant.

Common signs

Reduced height (2 standard deviations or more below age norms), undeveloped secondary sexual characteristics or premature ovarian insufficiency, reduced bone density. Elevated FSH and LH and reduced AMH and estradiol in peripheral blood.

Signs specific to the i(Xq) form

Frequency of cardiovascular malformations (bicuspid aortic valve, coarctation of the aorta) similar to classic Turner syndrome. Ultrasound findings of autoimmune thyroiditis (reduced thyroid echogenicity, heterogeneity). Abnormal glycemic control (impaired fasting glucose, abnormal glucose tolerance test). Elevated inflammatory markers (positive rheumatoid factor, ANA, anti-TPO antibodies).

Signs specific to the r(X) + absent XIST form

Cortical malformations and abnormal brain development on head MRI. Abnormal electroencephalogram (EEG) findings. Severe hypotonia (neonatal axial hypotonia). Feeding difficulties in infancy. Global delay on developmental testing. Autism spectrum features such as stereotyped behavior and avoidance of eye contact on behavioral observation.

Cardiovascular and renal (common)

Bicuspid aortic valve (relatively common in the i(Xq) form), horseshoe kidney and collecting system abnormalities. Hypertension (both secondary and primary possible).

8. Screening

Q96.4 variants are diagnosed through various clinical pathways.

Prenatal screening

cfDNA (NIPT) is useful for screening numerical sex chromosome aneuploidy (45,X) but has limitations in detecting structurally abnormal sex chromosomes such as i(Xq) or del(X). High-resolution cfDNA analysis offered by some institutions (based on whole-genome sequencing) can detect large structural abnormalities, but its sensitivity is low. Therefore, when cfDNA gives a positive result or there are abnormal ultrasound findings (cystic hygroma, cardiac malformations, etc.), invasive confirmatory testing (amniocentesis + karyotype + array CGH) is mandatory.

Childhood

Referral for karyotype analysis with growth delay, developmental delay (particularly when intellectual disability is present, consider the possibility of r(X) + absent XIST), delayed puberty or Turner physical features. Neonatal lymphedema and congenital heart malformations are also triggers for screening.

Adulthood

Found during evaluation of primary amenorrhea, premature ovarian insufficiency or infertility. It should also be suspected with a combination of recurrent autoimmune diseases (thyroiditis, rheumatic disease) and short stature.

9. Diagnosis

Diagnosis of Q96.4 requires a multistep cytogenetic-molecular genetic approach.

Biochemical tests: FSH, LH, E2, AMH. Thyroid function (TSH, fT4, anti-TPO antibodies). Fasting glucose, HbA1c. ANA, rheumatoid factor. Echocardiography, renal ultrasound, bone densitometry (DEXA). When r(X) + absent XIST is suspected, brain MRI, neurodevelopmental assessment and behavioral rating scales are performed.

10. Treatment

Treatment of Q96.4 is individualized to the phenotype of each variant.

Growth hormone and estrogen therapy

rhGH treatment for short stature is applied in the i(Xq) and del(Xp) forms in the same way as in classic Turner syndrome. Estrogen replacement and pubertal induction are given in all variants with ovarian failure, and hormone replacement therapy is maintained until age 50 to preserve bone density and cardiovascular health.

Management of autoimmune disease (i(Xq) form)

Regular assessment of thyroid function and levothyroxine replacement for hypothyroidism. Management of prediabetes (lifestyle modification, medication if necessary). Consultation with gastroenterology or rheumatology when inflammatory bowel disease or rheumatic disease is present.

Neurodevelopmental support (r(X) + absent XIST form)

Early intervention programs (speech therapy, occupational therapy, special education). Behavioral therapy for autism spectrum disorder (ABA, etc.). Anticonvulsant treatment if epilepsy develops. Long-term support from a multidisciplinary neurodevelopmental team (pediatric neurology, psychiatry, educational psychologist) is needed.

Gonadal management (sSMC containing Y sequences)

When Y-specific sequences (SRY, TSPY) are confirmed, prophylactic gonadectomy or regular gonadal ultrasound surveillance.

11. Prognosis

The prognosis of Q96.4 differs markedly with the type of abnormal sex chromosome.

i(Xq) mosaicism has a prognosis close to classic Turner syndrome, with relatively high risks of cardiovascular complications and autoimmune disease. Intellectual function is normal, and academic and occupational attainment are good. With appropriate hormone therapy and cardiovascular follow-up, life expectancy is close to normal.

The r(X) + XIST-containing form has a mild Turner phenotype with a relatively favorable prognosis. In contrast, the r(X) + absent XIST form requires long-term dependent support due to severe intellectual disability and multiple anomalies, and independent living is difficult. Early intervention programs have a significant effect on functional level and quality of life.

In the del(Xp) form, short stature and cardiovascular malformations are the main problems; in the del(Xq) form, premature ovarian insufficiency is the main problem, and management of loss of fertility and complications of long-term estrogen deficiency (osteoporosis, cardiovascular disease) is important. In the sSMC form containing Y sequences, appropriate gonadal management to prevent gonadoblastoma has a decisive effect on prognosis.

12. Prevention

Because Q96.4 occurs sporadically, primary prevention is difficult. However, a systematic approach to preventing complications and improving quality of life after diagnosis is needed.

Genetic counseling and prenatal diagnosis

When Q96.4 has been diagnosed in a previous child, invasive prenatal diagnosis (karyotype analysis + array CGH + FISH after amniocentesis or chorionic villus sampling) is recommended in the next pregnancy. cfDNA is used as an adjunctive screening tool. In prenatal diagnosis of complex variants including r(X) or an sSMC, the uncertainty of phenotype prediction (whether XIST is included, etc.) is fully explained in genetic counseling.

Monitoring for prevention of complications

In the i(Xq) type, perform regular testing for early detection of autoimmune diseases (thyroid, diabetes, inflammatory bowel disease). Track aortic diameter with cardiovascular MRI. Prevent osteoporosis with estrogen supplementation. In the r(X)+XIST-deficient type, early neurodevelopmental intervention can improve long-term functional prognosis, so refer to a multidisciplinary team immediately upon confirmation.

Patient and family support

Thorough education on the clinical features and prognosis of each variant type is needed. Especially in the r(X)+XIST-deficient type, psychosocial support for the family and linkage to educational resources are important. Establishing a long-term support plan through linkage with patient organizations and rare disease support systems is recommended.

13. References

  1. Gravholt CH, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome. Eur J Endocrinol. 2017;177(3):G1-G70. DOI: 10.1530/EJE-17-0430
  2. Sybert VP, McCauley E. Turner's syndrome. N Engl J Med. 2004;351(12):1227-1238. PMID: 15371580
  3. Migeon BR, et al. The severe phenotype of females with tiny ring X chromosomes is associated with inability of these chromosomes to undergo X inactivation. Am J Hum Genet. 1994;55(3):497-504. PMID: 8079993
  4. Leppig KA, Disteche CM. Ring X and other structural X chromosome abnormalities: X inactivation and phenotype. Semin Reprod Med.2001;19(2):147-157. PMID: 11480913
  5. Quilter CR, et al. The clinical phenotype associated with mosaic Turner syndrome and 46,X,i(Xq) cell lines. J Med Genet. 1996;33(4):324-329. PMID: 8730290
  6. Bianco B, et al. The frequency of gonadal dysgenesis in patients with Turner syndrome and its variants. Eur J Obstet Gynecol Reprod Biol. 2009;146(1):58-62. PMID: 19450911
  7. Stochholm K, et al. Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. J Clin Endocrinol Metab. 2006;91(10):3897-3902. PMID: 16849410
  8. Hook EB, Warburton D. Turner syndrome revisited: review of new data supports the hypothesis that all viable 45,X cases are cryptic mosaics with a rescue cell line. Hum Genet. 2014;133(4):417-424. PMID: 24362839
  9. Bondy CA. Turner Syndrome Study Group. Care of girls and women with Turner syndrome. J Clin Endocrinol Metab. 2007;92(1):10-25. PMID: 17047017
  10. Elsheikh M, et al. Turner syndrome in adulthood. Endocr Rev. 2002;23(1):120-140. PMID: 11844747